Skip to main content
SpringerLink
Log in

Daclatasvir in hepatitis C virus infection: a guide to its use in the EU

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Daclatasvir (Daklinza®), an inhibitor of hepatitis C virus (HCV) NS5A protein, is an oral, direct-acting antiviral with potent pangenotypic activity that approved in many countries worldwide. In the EU, it is approved for use in combination with other drugs for the treatment of chronic HCV genotype 1, 3 or 4 infection. Daclatasvir produces high sustained virological response rates in patients chronically infected with HCV genotypes 1–4 when used in combination with peginterferon-α + ribavirin or in combination with sofosbuvir (± ribavirin). Daclatasvir has a moderately high genetic barrier to resistance, is effective during short-term treatment over 12 weeks, has a safety and tolerability profile similar to that of placebo, has a relatively low potential for drug interactions, and is not associated with clinically relevant drug interactions with drugs commonly used in patients with HCV, including other antivirals and transplant medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. World Health Organization. Hepatitis C: fact sheet no. 164. 2014. http://www.who.int/mediacentre/factsheets/fs164/en/#. Accessed 21 Nov 2015.

  2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.

    Article  Google Scholar 

  3. Ashfaq UA, Javed T, Rehman S, et al. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:161.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420.

    Article  Google Scholar 

  5. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.

    Article  PubMed  CAS  Google Scholar 

  6. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  7. Daklinza (daclatasvir dihydrochloride): summary of product characteristics. London: European Medicines Agency; 2015.

  8. Daklinza (daclatasvir dihydrochloride) tablet: US prescribing information. Princeton: Bristol-Myers Squibb Company; 2015.

  9. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96–100.

    Article  PubMed  CAS  Google Scholar 

  10. Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA. 2013;110(10):3991–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Pelosi LA, Voss S, Liu M. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother. 2012;56:5230–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54(9):3641–50.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54(6):1924–35.

    Article  PubMed  CAS  Google Scholar 

  14. Wang C, Jia L, O’Boyle DR 2nd, et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother. 2014;58(9):5155–63.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18(7):931–40.

    Article  PubMed  CAS  Google Scholar 

  16. Garimella T, Gandhi Y, Wang R, et al. Daclatasvir exposure alone does not explain HCV relapse in HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir with ritonavir-boosted darunavir in the ALLY-2 study [abstract no. 728]. Hepatology. 2015;62(6 Suppl):572A.

    Google Scholar 

  17. Gandhi Y, Adamcyzk R, Wang R, et al. Assessment of drug-drug interactions between daclatasvir and darunavir/ritonavir or lopinavir/ritonavir [poster no. 80]. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; 2015.

  18. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–35.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Leroy V, Angus PW, Bronowicki J-P, et al. All-oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study [abstract no. LB-3]. Hepatology. 2015:62(6 Suppl):1380A–1381A.

  20. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.

    Article  PubMed  CAS  Google Scholar 

  21. Jacobson I, Zeuzem S, Flisiak R, et al. Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results [abstract no. 0213]. J Viral Hepat. 2014;21(Suppl S2):7–8.

  22. Hézode C, Alric L, Brown A, et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 2015. doi:10.3851/IMP2985.

    PubMed  Google Scholar 

  23. Hézode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2014;64(6):948–56.

    Article  PubMed  Google Scholar 

  24. Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Antivir Ther. 2014;19(5):501–10.

    Article  PubMed  CAS  Google Scholar 

  25. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. 2012;12(9):671–7.

    Article  PubMed  CAS  Google Scholar 

  26. Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther. 2014;19(5):491–9.

    Article  PubMed  CAS  Google Scholar 

  27. Dore GJ, Lawitz E, Hézode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015;148(2):355–66.e1.

  28. Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of phase 2b COMMAND-2 trial [abstract no. 1207, plus poster presented at the 47th Annual Meeting of the European Association for the Study of the Liver, 2012]. J Hepatol. 2012;56(Suppl 2):S478–9.

    Article  Google Scholar 

  29. US National Institutes of Health. ClinicalTrials.gov. 2015. http://clinicaltrials.gov/. Accessed 30 Nov 2015.

  30. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384(9954):1597–605.

    Article  PubMed  CAS  Google Scholar 

  31. Jensen D, Sherman KE, Hézode C, et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015;63(1):30–7.

    Article  PubMed  CAS  Google Scholar 

  32. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–25.

    Article  PubMed  Google Scholar 

  33. McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. Drugs. 2015;75(5):515–24.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The review was updated from Drugs 2015; 75(5):515–24 [33], and was reviewed by: A. Antonelli, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; F. Araujo, Faculty of Experimental Sciences, Pablo de Olavide University, Seville, Spain; F. Bessone, Department of Gastroenterology and Hepatology, University of Rosario School of Medicine, Rosario, Argentina; S. Mirkov, Auckland, New Zealand; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India. During the peer review process, the manufacturer of daclatasvir was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Paul L. McCormack & Katherine A. Lyseng-Williamson

Authors
  1. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul L. McCormack.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

P. L. McCormack and K. A. Lyseng-Williamson are salaried employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCormack, P.L., Lyseng-Williamson, K.A. Daclatasvir in hepatitis C virus infection: a guide to its use in the EU. Drugs Ther Perspect 32, 42–49 (2016). https://doi.org/10.1007/s40267-015-0272-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0272-3

Keywords

Search

Navigation